Patents by Inventor Martin James Wythes

Martin James Wythes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulators of STING (Stimulator of Interferon Genes)
    Publication number: 20240383903
    Abstract: Provided herein are compounds of the general formula (I): and pharmaceutically acceptable salts thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
    Type: Application
    Filed: March 18, 2024
    Publication date: November 21, 2024
    Applicant: PFIZER INC.
    Inventors: Ketan Satish GAJIWALA, Chan Woo HUH, Mehran JALAIE, Ryan Lloyd PATMAN, Eugene Yuanjin RUI, Jianmin SUN, Martin James WYTHES
  • Modulators of STING (stimulator of interferon genes)
    Patent number: 11964978
    Abstract: Provided herein are compounds of the general formula (I): and pharmaceutically acceptable salts thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
    Type: Grant
    Filed: March 11, 2022
    Date of Patent: April 23, 2024
    Assignee: PFIZER INC.
    Inventors: Ketan Satish Gajiwala, Chan Woo Huh, Mehran Jalaie, Ryan Lloyd Patman, Eugene Yuanjin Rui, Jianmin Sun, Martin James Wythes
  • Cyclopentane-Based Modulators of STING (Stimulator of Interferon Genes)
    Publication number: 20230382932
    Abstract: Compounds of the general formula (I): or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
    Type: Application
    Filed: July 24, 2023
    Publication date: November 30, 2023
    Applicant: PFIZER INC.
    Inventors: Martin James WYTHES, Indrawan James MCALPINE, Ryan PATMAN, Eugene Yuanjin RUI, Andrew FENSOME, Andreas MADERNA, Mehran JALAIE, Ketan S. GAJIWALA
  • Modulators of STING (Stimulator of Interferon Genes)
    Publication number: 20220306641
    Abstract: Provided herein are compounds of the general formula (I): and pharmaceutically acceptable salts thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
    Type: Application
    Filed: March 11, 2022
    Publication date: September 29, 2022
    Applicant: PFIZER INC.
    Inventors: Ketan Satish GAJIWALA, Chan Woo HUH, Mehran JALAIE, Ryan Lloyd PATMAN, Eugene Yuanjin RUI, Jianmin SUN, Martin James WYTHES
  • Cyclopentane-Based Modulators of STING (Stimulator of Interferon Genes)
    Publication number: 20210230196
    Abstract: Compounds of the general formula (I): or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
    Type: Application
    Filed: March 3, 2021
    Publication date: July 29, 2021
    Applicant: Pfizer Inc.
    Inventors: Martin James Wythes, Indrawan James McAlpine, Ryan Patman, Eugene Yuanjin Rui, Andrew Fensome, Andreas Maderna, Mehran Jalaie, Ketan S. Gajiwala
  • Cyclopentane-based modulators of STING (stimulator of interferon genes)
    Patent number: 10968242
    Abstract: Compounds of the general formula (I): or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: April 6, 2021
    Assignee: Pfizer Inc.
    Inventors: Martin James Wythes, Indrawan James McAlpine, Ryan Patman, Eugene Yuanjin Rui, Andreas Maderna, Mehran Jalaie, Ketan S. Gajiwala
  • Modulators of STING (Stimulator of Interferon Genes)
    Publication number: 20210087180
    Abstract: Compounds of the general formula (I): or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
    Type: Application
    Filed: September 23, 2020
    Publication date: March 25, 2021
    Applicant: PFIZER INC.
    Inventors: Ryan PATMAN, Martin James WYTHES, Eugene Yuanjin RUI, Indrawan James MCALPINE, Andrew FENSOME, Mehran JALAIE, Ketan S. GAJIWALA, Chan Woo HUH, Tuan Phong TRAN, Lei ZHANG, Dahui ZHOU, Ethan Lawrence FISHER
  • Substituted carbonucleoside derivatives useful as anticancer agents
    Patent number: 10709709
    Abstract: Compounds of the general formula): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: July 14, 2020
    Assignee: Pfizer Inc.
    Inventors: John Howard Tatlock, Indrawan James McAlpine, Michelle Bich Tran-Dube, Eugene Yuanjin Rui, Martin James Wythes, Robert Arnold Kumpf, Michele Ann McTigue, Ryan Patman
  • Cyclopentane-Based Modulators of STING (Stimulator of Interferon Genes)
    Publication number: 20200102334
    Abstract: Compounds of the general formula (I): or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
    Type: Application
    Filed: December 4, 2019
    Publication date: April 2, 2020
    Applicant: Pfizer Inc.
    Inventors: Martin James Wythes, Indrawan James McAlpine, Ryan Patman, Eugene Yuanjin Rui, Andrew Fensome, Andreas Maderna, Mehran Jalaie, Ketan S. Gajiwala
  • Substituted dihydroisoquinolinone compounds
    Patent number: 10570121
    Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: February 25, 2020
    Assignee: Pfizer Inc.
    Inventors: Michael Raymond Collins, Robert Steven Kania, Robert Arnold Kumpf, Pei-Pei Kung, Daniel Tyler Richter, Scott Channing Sutton, Martin James Wythes
  • Cyclopentane-based modulators of STING (stimulator of interferon genes)
    Patent number: 10538542
    Abstract: Compounds of the general formula (I): or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: January 21, 2020
    Assignee: Pfizer Inc.
    Inventors: Martin James Wythes, Indrawan James McAlpine, Ryan Patman, Eugene Yuanjin Rui, Andrew Fensome, Andreas Maderna, Mehran Jalaie, Ketan S. Gajiwala
  • Substituted nucleoside derivatives useful as anticancer agents
    Patent number: 10428104
    Abstract: Compounds such as: processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds to treat neoplasms have been disclosed.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: October 1, 2019
    Assignee: Pfizer Inc.
    Inventors: John Howard Tatlock, Indrawan James McAlpine, Michelle Bich Tran-Dube, Eugene Yuanjin Rui, Martin James Wythes, Robert Arnold Kumpf, Michele Ann McTigue
  • Cyclopentane-Based Modulators of STING (Stimulator of Interferon Genes)
    Publication number: 20190284216
    Abstract: Compounds of the general formula (I): or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
    Type: Application
    Filed: March 11, 2019
    Publication date: September 19, 2019
    Applicant: Pfizer Inc.
    Inventors: Martin James Wythes, Indrawan James McAlpine, Ryan Patman, Eugene Yuanjin Rui, Andrew Fensome, Andreas Maderna, Mehran Jalaie, Ketan S. Gajiwala
  • SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS
    Publication number: 20190111060
    Abstract: Compounds of the general formula): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
    Type: Application
    Filed: December 18, 2018
    Publication date: April 18, 2019
    Applicant: Pfizer Inc.
    Inventors: John Howard Tatlock, Indrawan James McAlpine, Michelle Bich Tran-Dube, Eugene Yuanjin Rui, Martin James Wythes, Robert Arnold Kumpf, Michele Ann McTigue, Ryan Patman
  • Aryl and heteroaryl fused lactams
    Patent number: 10246433
    Abstract: This invention relates to compounds of general formula (I) in which R1, R2, U, V, L, M, R5, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: April 2, 2019
    Assignee: Pfizer Inc.
    Inventors: Martin Paul Edwards, Robert Arnold Kumpf, Pei-Pei Kung, Indrawan James McAlpine, Sacha Ninkovic, Eugene Yuanjin Rui, Scott Channing Sutton, John Howard Tatlock, Martin James Wythes, Luke Raymond Zehnder
  • Substituted carbonucleoside derivatives useful as anticancer agents
    Patent number: 10220037
    Abstract: Compounds of the general formula): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: March 5, 2019
    Assignee: Pfizer Inc.
    Inventors: John Howard Tatlock, Indrawan James McAlpine, Michelle Bich Tran-Dube, Eugene Yuanjin Rui, Martin James Wythes, Robert Arnold Kumpf, Michele Ann McTigue, Ryan Patman
  • SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS
    Publication number: 20190040047
    Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Application
    Filed: October 10, 2018
    Publication date: February 7, 2019
    Applicant: Pfizer Inc.
    Inventors: Michael Raymond Collins, Robert Steven Kania, Robert Arnold Kumpf, Pei-Pei Kung, Daniel Tyler Richter, Scott Channing Sutton, Martin James Wythes
  • SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS
    Publication number: 20170348313
    Abstract: Compounds of the general formula): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
    Type: Application
    Filed: June 2, 2017
    Publication date: December 7, 2017
    Applicant: Pfizer Inc.
    Inventors: John Howard Tatlock, Indrawan James McAlpine, Michelle Bich Tran-Dube, Eugene Yuanjin Rui, Martin James Wythes, Robert Arnold Kumpf, Michele Ann McTigue, Ryan Patman
  • SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS
    Publication number: 20170298048
    Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Application
    Filed: June 28, 2017
    Publication date: October 19, 2017
    Applicant: Pfizer Inc.
    Inventors: Michael Raymond Collins, Robert Steven Kania, Robert Arnold Kumpf, Pei-Pei Kung, Daniel Tyler Richter, Scott Channing Sutton, Martin James Wythes
  • ARYL AND HETEROARYL FUSED LACTAMS
    Publication number: 20170233368
    Abstract: This invention relates to compounds of general formula (I) in which R1, R2, U, V, L, M, R5, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Application
    Filed: May 3, 2017
    Publication date: August 17, 2017
    Applicant: Pfizer Inc.
    Inventors: Martin Paul EDWARDS, Robert Arnold KUMPF, Pei-Pei KUNG, lndrawan James MCALPINE, Sacha NINKOVIC, Eugene Yuanjin RUI, Scott Channing SUTTON, John Howard TATLOCK, Martin James WYTHES, Luke Raymond ZEHNDER